Monthly Prescribing Reference5h
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
Managed Healthcare Executive1d
FDA Requires Guillain-Barré Warning for Abrysvo and Arexvy
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
cidrap.umn2d
FDA requires Guillain-Barre label warnings for 2 RSV vaccines
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
Healio2d
FDA says RSV vaccines must come with Guillain-Barré warning
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Hosted on MSN2d
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...